Last reviewed · How we verify
SIM0718 Injection
SIM0718 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses.
SIM0718 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses. Used for Chronic hepatitis B, Chronic hepatitis C.
At a glance
| Generic name | SIM0718 Injection |
|---|---|
| Sponsor | Simcere Pharmaceutical Co., Ltd |
| Drug class | Interferon alpha fusion protein |
| Target | Interferon alpha receptor (IFNAR) |
| Modality | Biologic |
| Therapeutic area | Virology / Immunology |
| Phase | Phase 3 |
Mechanism of action
SIM0718 combines human serum albumin with interferon alpha to improve the pharmacokinetic properties and biological activity of interferon. The albumin fusion extends the half-life and reduces immunogenicity while maintaining interferon alpha's ability to activate innate immune responses and inhibit viral replication through JAK-STAT signaling pathways.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
Common side effects
- Flu-like symptoms
- Fatigue
- Fever
- Headache
- Myalgia
Key clinical trials
- SIM0718 Treatment of Asthma Clinical Study (PHASE3)
- A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China (PHASE1)
- A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |